{"filing":{"accession_number":"0001213900-26-095370","cik":"0001871321","ticker":"DRTSW","company_name":"Alpha Tau Medical Ltd.","form":"6-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"ea0303693-6k_alpha.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1871321/000121390026095370/ea0303693-6k_alpha.htm"},"events":[{"id":30497,"run_id":27948,"accession_number":"0001213900-26-095370","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces completion of patient enrollment in the IMPACT clinical trial for Alpha DaRT in pancreatic cancer, with enrollment expanded three times from 12 to 48 patients. The disclosure highlights a significant operational and clinical milestone — successful rapid enrollment in a pivotal pilot study that will inform design of a planned pivotal trial — which is material to investors assessing the company's clinical development progress and commercial prospects for its lead therapeutic candidate. The event does not fit a discrete named category (not an earnings release, M\u0026A activity, executive change, or other specific event type), but is clearly a material operational/clinical development milestone.","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-08-31","form":"6-K","submitted_at":null,"items":[{"id":33107,"accession_number":"0001213900-26-095370","item_number":"EX-99.1","item_title":"ea030369301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of patient enrollment in the IMPACT clinical trial for Alpha DaRT in pancreatic cancer, with enrollment expanded three times from 12 to 48 patients. The disclosure highlights a significant operational and clinical milestone — successful rapid enrollment in a pivotal pilot study that will inform design of a planned pivotal trial — which is material to investors assessing the company's clinical development progress and commercial prospects for its lead therapeutic candidate. The event does not fit a discrete named category (not an earnings release, M\u0026A activity, executive change, or other specific event type), but is clearly a material operational/clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T12:01:05.523075+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33107,"accession_number":"0001213900-26-095370","item_number":"EX-99.1","item_title":"ea030369301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of patient enrollment in the IMPACT clinical trial for Alpha DaRT in pancreatic cancer, with enrollment expanded three times from 12 to 48 patients. The disclosure highlights a significant operational and clinical milestone — successful rapid enrollment in a pivotal pilot study that will inform design of a planned pivotal trial — which is material to investors assessing the company's clinical development progress and commercial prospects for its lead therapeutic candidate. The event does not fit a discrete named category (not an earnings release, M\u0026A activity, executive change, or other specific event type), but is clearly a material operational/clinical development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-31T12:01:05.523075+00:00","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-08-31"}]}